Satogler FCT 10 mg & 20 mg

Satogler is indicated as an adjunct to diet to reduce elevated total-C, LDL-C and TG levels in patients with primary hypercholesterolemia or mixed dyslipidemia where the primary abnormality is either elevated cholesterol or triglycerides when response to diet and other non-pharmacological measures is inadequate.

Satogler is also indicated to reduce total-C and LDL-C in patients with heterozygous and homozygous familial hypercholesterolemia.              

Satogler is indicated to increase plasma HDL-C and decrease the LDL-C/HDL-C and total cholesterol/HDL-C ratios.

Satogler is indicated as an adjunct to diet for the treatment of patients with elevated serum triglyceride levels (hypertriglyceridemia), and for the treatment of patients with Dysbetalipoproteinemia who do not respond adequately to diet.

Satogler is indicated for the reduction of cardiac ischemic events in patients with asymptomatic or mildly to moderately symptomatic coronary artery disease with a LDL-cholesterol of at least 3.0 mmol/L and a triglyceride level of no more than 5.6 mmol/L.

Satogler is indicated in hypertensive patients with multiple risk factors for coronary heart disease (CHD), which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic CHD (see Clinical Trials) to reduce the risk of non-fatal myocardial infarction and non-fatal stroke.                       

Satogler is also indicated in patients with type 2 diabetes, with at least one other risk factor for CHD, to reduce the risk of coronary and cerebrovascular events.

These effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Packing:

Satogler 10 mg Carton box contains 3 blisters* 10 tablets

Satogler 20 mg Carton box contains 3 blisters* 10 tablets